MedTrace Logo

Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)

NCT04291287 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2020-03-26

No results posted yet for this study

Summary

Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single antiplatelet therapy+anticoagulant) after percutaneous coronary intervention (PCI). Investigator's driven trial, retrospective (2015-2019), multicenter Italian registry. Baseline clinical characteristics as well as procedural details will be collected retrospectively. Follow-up data (minimum 6 months and maximum 5 years follow-up) will focus on combined rates of stent thrombosis and myocardial infarction (primary endpoint).

Conditions

Interventions

DRUG

Antithrombotic Agent

Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include: * Clopidogrel (Plavix®) * Prasugrel (Efient®) * Ticagrelor (Brilique®) DOACs therapy include: * Apixaban (Eliquis®) * Dabigatran (Pradaxa®) * Edoxaban (Lixiana®) * Rivaroxaban (Xarelto®). Oral anticoagulant therapy (OAT) include: * Warfarin (Counmadin®) * Acenocumarol (Sintrom®)

Sponsors & Collaborators

  • Scientific Institute San Raffaele

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-25
Primary Completion
2022-02-28
Completion
2022-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04291287 on ClinicalTrials.gov